Bristol Myers Squibb - Eight-Year Data for Opdivo Plus Yervoy Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
PRINCETON - Bristol Myers Squibb today announced that Opdivo plus Yervoy continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28%...